

Financial news for VSTM dated on 2020-05-11: H.C. Wainwright Reiterates Buy on Verastem, Raises Price Target to \$3

Financial news for VSTM dated on 2020-05-07: Verastem Oncology Q4 EPS \$(0.400) Beats \$(0.450) Estimate, Sales \$3.617M Miss \$4.500M Estimate

Financial news for VSTM dated on 2020-05-04: Traders Circulate May 4-Dated ClinicalTrials.gov Trial Record For Verastem's Duvelisib To Combat Coronavirus; Recruitment Status Shows 'Not Yet Recruiting'

Financial news for VSTM dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for VSTM dated on 2020-04-29: 82 Biggest Movers From Yesterday

Financial news for VSTM dated on 2020-04-28: 56 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VSTM dated on 2020-04-28: Verastem Option Alert: Jun 19 \$3 Calls Sweep (2) near the Ask: 475 @ \$0.25 vs 11420 OI; Earnings 5/11 After Close [est] Ref=\$2.085

Financial news for VSTM dated on 2020-04-28: 96 Biggest Movers From Yesterday

Financial news for VSTM dated on 2020-04-27: Mid-Afternoon Market Update: Dow Surges 350 Points; CNX Midstream Partners Shares Plummet

Financial news for VSTM dated on 2020-04-27: Verastem Files Prospectus Related To Resale Or Other Disposition Of Up To 46.5M Shares Of Common Stock By Selling Shareholders

Financial news for VSTM dated on 2020-04-27: 72 Stocks Moving In Monday's Mid-Day Session

Financial news for VSTM dated on 2020-04-27: Mid-Day Market Update: Crude Oil Slides 28%; Avadel Pharmaceuticals Shares Climb

Financial news for VSTM dated on 2020-04-27: P/E Ratio Insights for Verastem

Financial news for VSTM dated on 2020-04-27: Morning Market Stats in 5 Minutes

Financial news for VSTM dated on 2020-04-27: Mid-Morning Market Update: Markets Open Higher; Deutsche Bank Projects To Report Strong Q1 Results

Financial news for VSTM dated on 2020-04-27: Verastem shares are trading lower after the company provided response rate data from its phase 1 study of VS-6766 in mutant tumors.

Financial news for VSTM dated on 2020-04-27: 33 Stocks Moving in Monday's Pre-Market Session

Financial news for VSTM dated on 2020-04-27: Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at AACR 2020 Virtual Annual Meeting I

Financial news for VSTM dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for VSTM dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for VSTM dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for VSTM dated on 2020-04-23: The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Financial news for VSTM dated on 2020-04-22: Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash.

Financial news for VSTM dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for VSTM dated on 2020-04-21: 78 Biggest Movers From Yesterday

Financial news for VSTM dated on 2020-04-20: 54 Stocks Moving In Monday's Mid-Day

Session

Financial news for VSTM dated on 2020-04-20: Stocks That Hit 52-Week Highs On Monday

Financial news for VSTM dated on 2020-04-07: Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for VSTM dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for VSTM dated on 2020-03-16: Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.

Financial news for VSTM dated on 2020-03-16: H.C. Wainwright Maintains Buy on Verastem, Raises Price Target to \$2.75

Financial news for VSTM dated on 2020-03-12: 90 Biggest Movers From Yesterday

Financial news for VSTM dated on 2020-03-11: Verastem Oncology Expects Its R&D and SG&A Expenses For FY20 To Be In The Range Of \$70M - \$85M

Financial news for VSTM dated on 2020-03-11: Verastem Oncology Q4 EPS \$(0.51) Down From \$(0.37) YoY, Sales \$3.617M Up From \$1.21M YoY

Financial news for VSTM dated on 2020-03-11: 78 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VSTM dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for VSTM dated on 2020-03-09: 100 Biggest Movers From Friday

Financial news for VSTM dated on 2020-03-03: 40 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSTM dated on 2020-03-03: Cantor Fitzgerald Maintains Overweight on Verastem, Raises Price Target to \$6

Financial news for VSTM dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for VSTM dated on 2020-02-28: 86 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2020-02-28: Verastem Oncology shares are trading higher after the company announced a strategic direction to accelerate the development of CH5126766 for the treatment of KRAS mutant solid tumors.

Financial news for VSTM dated on 2020-02-28: 50 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2020-02-28: Verastem Sees FY20 R&D, SG&A Expenses \$70M-\$85M

Financial news for VSTM dated on 2020-02-28: Verastem Highlights New Strategic Direction: Will Accelerate Development Of VS-6766, Defactinib Combo, Duvelisib, Focus On Commercial Activities For COPIKTRA

Financial news for VSTM dated on 2020-02-28: Verastem Reports \$100M Private Placement Of Common Stock To Premier Life Sciences Investors

Financial news for VSTM dated on 2020-02-04: Verastem shares are trading higher after Point72 reported a 7.4% passive stake in the company.

Financial news for VSTM dated on 2020-02-03: Point72 Reports 7.4% Passive Stake In Verastem

Financial news for VSTM dated on 2020-01-29: Verastem Oncology Announces Dosing Of First Patient In CSPC's Chinese Study Evaluating COPIKTRA In Patients With Relapsed Or Refractory Follicular Lymphoma

Financial news for VSTM dated on 2020-01-29: Verastem Oncology Announces Dosing of First Patient in CSPC's Chinese Study Evaluating COPIKTRA in Patients with Relapsed or Refractory Follicular Lymphoma

Financial news for VSTM dated on 2020-01-23: 15 Biotechnology Stocks Moving In Thursday's After-Market Session

Financial news for VSTM dated on 2020-01-23: 20 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for VSTM dated on 2020-01-08: 50 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chugai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for VSTM dated on 2020-01-08: Verastem Oncology shares are trading higher after the company announced a global licensing agreement with Chugai Pharmaceutical to develop and commercialize RAF/MEK Inhibitor CH5126766.

Financial news for VSTM dated on 2020-01-08: Verastem Oncology Announces Global Licensing Agreement With Chugai Pharmaceutical Co., Ltd. To Develop And Commercialize RAF/MEK Inhibitor CH5126766; Co. To Make \$3M Upfront Payment To Chugai And Pay Royalties

Financial news for VSTM dated on 2019-12-18: 30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for VSTM dated on 2019-12-07: Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

Financial news for VSTM dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for VSTM dated on 2019-11-26: Verastem Oncology shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock is trading on above-average volume.

Financial news for VSTM dated on 2019-11-25: Verastem Reports Submission Of Marketing Authorization Application To EMA For COPIKTRA

Financial news for VSTM dated on 2019-11-22: Verastem Shares Spike ~20% As Traders Circulate Word Of New Buy Recommendation By Unknown Newsletter

Financial news for VSTM dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for VSTM dated on 2019-11-18: Stocks That Hit 52-Week Lows On Monday

Financial news for VSTM dated on 2019-11-15: Stocks That Hit 52-Week Lows On Friday

Financial news for VSTM dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for VSTM dated on 2019-11-14: Stocks That Hit 52-Week Lows On Thursday

Financial news for VSTM dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for VSTM dated on 2019-11-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VSTM dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for VSTM dated on 2019-11-12: Stocks That Hit 52-Week Lows On Tuesday

Financial news for VSTM dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for VSTM dated on 2019-10-29: Verastem Reaffirms FY19 Guidance, Sees COPIKTRA Sales \$12M-\$14M

Financial news for VSTM dated on 2019-10-29: Verastem Oncology Q3 Adj. EPS \$(0.35) Beats \$(0.46) Estimate, Sales \$9.03M Beat \$8.95M Estimate

Financial news for VSTM dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes

Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for VSTM dated on 2019-10-23: 33 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2019-10-23: Verastem Oncology Highlights COPIKTRA Presentations At Lymphoma & Myeloma 2019 Int'l. Congress

Financial news for VSTM dated on 2019-10-15: The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

Financial news for VSTM dated on 2019-10-14: Stocks That Hit 52-Week Lows On Monday

Financial news for VSTM dated on 2019-10-10: 5 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for VSTM dated on 2019-10-07: Verastem Oncology Doses its First Patient in Yakult Honsha's Study Evaluating COPIKTRA

Financial news for VSTM dated on 2019-10-03: Verastem Oncology Receives Orphan Drug Designation From FDA For COPIKTRA For The Treatment Of T-Cell Lymphoma

Financial news for VSTM dated on 2019-10-03: The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo

Financial news for VSTM dated on 2019-10-02: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VSTM dated on 2019-08-08: 25 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for VSTM dated on 2019-08-02: Verastem Oncology shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Financial news for VSTM dated on 2019-08-01: Verastem Oncology Q2 EPS \$(0.57) Misses \$(0.5) Estimate, Sales \$3M Beat \$2.32M Estimate

Financial news for VSTM dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for VSTM dated on 2019-08-01: 28 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for VSTM dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for VSTM dated on 2019-07-29: 30 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for VSTM dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for VSTM dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for VSTM dated on 2019-07-26: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for VSTM dated on 2019-07-26: Verastem Oncology shares are trading higher after the company signed an exclusive license agreement with Sanofi for the development and commercialization of COPIKTRA in Russia and CIS, Turkey, the Middle East and Africa.

Financial news for VSTM dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for VSTM dated on 2019-07-26: 30 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for VSTM dated on 2019-07-25: Verastem Oncology Signs An Exclusive License Agreement With Sanofi For The Development And Commercialization Of COPIKTRA In Russia And CIS, Turkey, The Middle East And Africa; Co. To Receive \$5M Upfront, Up To \$42M In Milestones

Financial news for VSTM dated on 2019-06-24: 68 Biggest Movers From Friday

Financial news for VSTM dated on 2019-06-21: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2019-06-21: Verastem Shares Response Rate From COPIKTRA Data

Financial news for VSTM dated on 2019-06-21: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2019-06-21: UPDATE: Verastem Says Data From Two Phase 1 Studies Show Response Rates Of 44-57%, Including Complete Response Rates Of 15-22%

Financial news for VSTM dated on 2019-06-21: Verastem Oncology Highlights Presentation Of COPIKTRA Data In Peripheral T-Cell Lymphoma At 2019 International Conference On Malignant Lymphoma

Financial news for VSTM dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for VSTM dated on 2019-06-17: Verastem Oncology Presents COPIKTRA Data at the European Hematology Association 2019 Annual Meeting

Financial news for VSTM dated on 2019-05-15: Verastem Oncology Highlights Will Present New COPIKTRA(tm) Dose Modification Data from Patients Treated in the Phase 3 DUO Study At ASCO

Financial news for VSTM dated on 2019-05-10: Verastem Oncology shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results; Raymond James also downgraded the company's stock from Outperform to Market Perform.

Financial news for VSTM dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for VSTM dated on 2019-05-10: Raymond James Downgrades Verastem, Inc. - Common Stock to Market Perform

Financial news for VSTM dated on 2019-05-09: Verastem Oncology shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.

Financial news for VSTM dated on 2019-05-09: Verastem Q1 EPS \$(0.52) Misses \$(0.47) Estimate, Sales \$1.671M Miss \$2.91M Estimate

Financial news for VSTM dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for VSTM dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for VSTM dated on 2019-05-03: The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

Financial news for VSTM dated on 2019-04-18: The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

Financial news for VSTM dated on 2019-04-16: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

Financial news for VSTM dated on 2019-04-16: 44 Biggest Movers From Yesterday

Financial news for VSTM dated on 2019-04-03: Benzinga's Top Upgrades, Downgrades For April 3, 2019

Financial news for VSTM dated on 2019-04-03: Cantor Fitzgerald Initiates Coverage On Verastem Oncology with Overweight Rating, Announces \$5 Price Target

Financial news for VSTM dated on 2019-04-02: Verastem Oncology To Present At H.C. Wainwright Global Life Sciences Conference

Financial news for VSTM dated on 2019-03-13: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VSTM dated on 2019-03-13: Verastem Oncology shares are trading lower after the company reported worse-than-expected Q4 sales.

Financial news for VSTM dated on 2019-03-13: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2019-03-13: The Daily Biotech Pulse: AEterna

Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Financial news for VSTM dated on 2019-03-12: Verastem Oncology shares are trading lower after the company reported lower-than-expected Q4 sales results.

Financial news for VSTM dated on 2019-03-12: Verastem Q4 EPS \$(0.37) Beats \$(0.53) Estimate, Sales \$1.21M Miss \$2.92M Estimate

Financial news for VSTM dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for VSTM dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for VSTM dated on 2019-03-07: Verastem Oncology Highlights Presentation Of COPIKTRA (Duvelisib) Data At The 23rd Annual International Congress On Hematologic Malignancies

Financial news for VSTM dated on 2019-02-14: Verastem Oncology Highlights Publication Of Phase 2 DYNAMO Study Results In Indolent Non-Hodgkin Lymphoma In The Journal Of Clinical Oncology

Financial news for VSTM dated on 2019-01-14: 44 Biggest Movers From Friday

Financial news for VSTM dated on 2019-01-09: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2019-01-04: The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

Financial news for VSTM dated on 2019-01-03: Verastem Oncology Outlines Strategic Priorities For 2019

Financial news for VSTM dated on 2018-12-20: Verastem Shareholders Approve Amendment To Increase Number Of Authorized Common Shares From 100M To 200M Shares

Financial news for VSTM dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for VSTM dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for VSTM dated on 2018-11-08: 88 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-11-07: Verastem, Inc. Q3 EPS \$(0.29) Beats \$(0.42) Estimate, Sales \$15.508M

Financial news for VSTM dated on 2018-11-07: Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For Peripheral T-Cell Lymphoma

Financial news for VSTM dated on 2018-10-15: 44 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-10-12: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2018-10-08: Verastem Oncology's COPIKTRA Capsules Added to the National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology

Financial news for VSTM dated on 2018-10-05: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2018-10-05: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2018-10-02: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VSTM dated on 2018-10-02: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSTM dated on 2018-09-27: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for VSTM dated on 2018-09-26: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for VSTM dated on 2018-09-26: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VSTM dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for VSTM dated on 2018-09-26: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2018-09-26: 51 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-09-25: 6 Stocks Moving In Tuesday's After-Hours Session

Financial news for VSTM dated on 2018-09-25: Verastem shares are up 7.8% after the company signed an exclusive license agreement with CSPC Pharmaceutical Group for the development and commercialization of COPIKTRA in China.

Financial news for VSTM dated on 2018-09-25: Verastem Oncology Signs Exclusive License Agreement For Development And Commercialization Of COPIKTRA (duvelisib) In China; Veristem Will Receive Upfront Payment Of \$15M, Will Be Eligible For Up To \$30M In Milestones

Financial news for VSTM dated on 2018-09-25: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VSTM dated on 2018-09-24: Verastem In 8-K Says Says COPIKTRA Will Be Available In US Market Immediately

Financial news for VSTM dated on 2018-09-24: Verastem Shares Resume Trade, Up 7%

Financial news for VSTM dated on 2018-09-24: Verastem Shares To Resume Trade At 4:20 p.m. EDT

Financial news for VSTM dated on 2018-09-24: Verastem Reports FDA Approval Of COPIKTRA Capsules

Financial news for VSTM dated on 2018-09-24: Watching Shares Of Verastem As Document On FDA Site Appears To Highlight Approval For COPIKTRA (duvelisib) Capsules For Oral Use

Financial news for VSTM dated on 2018-09-24: Verastem Shares Halted, News Pending

Financial news for VSTM dated on 2018-09-06: Verastem Reports Investigator-Sponsored Study On Duvelisib In Combo With Venetoclax

Financial news for VSTM dated on 2018-09-05: Court Filing Shows A US Judge Has Blocked State Of Texas's Fetal Tissue Burial Law

Financial news for VSTM dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for VSTM dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for VSTM dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for VSTM dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for VSTM dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for VSTM dated on 2018-08-29: Verastem Oncology Names Robert Gagnon CFO

Financial news for VSTM dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetrphase's Antibiotic

Financial news for VSTM dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for VSTM dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for VSTM dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for VSTM dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for VSTM dated on 2018-08-09: Versatem shares are trading 15% higher on high volume after the company reported strong quarterly financial results.

Financial news for VSTM dated on 2018-08-08: Verastem Q2 EPS \$(0.30) Beats \$(0.34) Estimate, Sales \$10M May Not Compare To \$1.35M Estimate

Financial news for VSTM dated on 2018-07-24: Verastem S-3 Shows Registration For \$200M Mixed Securities Shelf Offering

Financial news for VSTM dated on 2018-07-16: 38 Biggest Movers From Friday

Financial news for VSTM dated on 2018-07-13: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2018-07-13: Benzinga's Top Upgrades, Downgrades For July 13, 2018

Financial news for VSTM dated on 2018-07-13: BTIG Research Initiates Coverage On Verastem with Buy Rating, Announces \$17 Price Target

Financial news for VSTM dated on 2018-07-11: 41 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-07-10: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VSTM dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for VSTM dated on 2018-06-19: Benzinga Pro's Top 10 Most-Searches Tickers For Afternoon Of Tues., Jun. 19, 2018

Financial news for VSTM dated on 2018-06-19: Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Financial news for VSTM dated on 2018-06-19: 60 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-06-18: Veristem Shares Closed Up 30.9% After Co.'s Duvelisib Showed Robust Clinical Activity In CLL

Financial news for VSTM dated on 2018-06-18: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher

Financial news for VSTM dated on 2018-06-18: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for VSTM dated on 2018-06-18: Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide

Financial news for VSTM dated on 2018-06-18: Verastem Shares Hit Highest Level Since 2015 On Duvelisib Data

Financial news for VSTM dated on 2018-06-18: Benzinga Pro's Top 10 Most-Searches Tickers For Morning Of Mon., Jun. 18, 2018

Financial news for VSTM dated on 2018-06-18: Veristem Shares Up 14.2% Premarket After Co.'s Duvelisib Showed Robust Clinical Activity In CLL

Financial news for VSTM dated on 2018-06-18: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for VSTM dated on 2018-06-18: 40 Biggest Movers From Friday

Financial news for VSTM dated on 2018-06-15: Mid-Afternoon Market Update: Crude Oil Down Over 3%; Canada Goose Shares Gain Following Strong Q4 Results

Financial news for VSTM dated on 2018-06-15: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for VSTM dated on 2018-06-15: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2018-06-15: 7 Stocks To Watch For June 15, 2018

Financial news for VSTM dated on 2018-06-14: 7 Stocks Moving In Thursday's After-Hours Session

Financial news for VSTM dated on 2018-06-14: UPDATE: Verastem Offering Prices 7,166,666 Shares Common Stock at \$6/Share

Financial news for VSTM dated on 2018-06-14: Verastem Oncology Announces \$43M Common Stock Offering

Financial news for VSTM dated on 2018-06-07: Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Financial news for VSTM dated on 2018-06-07: 40 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-06-06: Hearing Agora Financial's Ray Blanco Of Breakthrough Technology Alert Is Out Positive On Verastem With A \$15 Price Target

Financial news for VSTM dated on 2018-06-06: 45 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-06-05: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VSTM dated on 2018-06-05: Benzinga Pro's 5 Stocks To Watch Today

Financial news for VSTM dated on 2018-06-05: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSTM dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for VSTM dated on 2018-06-05: Verastem Oncology, Yakult Honsha Co., Ltd. Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan; Verastem to Receive \$10M Upfront Payment; Up to Additional \$90M for Milestones

Financial news for VSTM dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for VSTM dated on 2018-06-01: Verastem 8-K Shows News CFO Julie Feder Resigned; COO Daniel Paterson Named Principal Financial Officer On Interim Basis

Financial news for VSTM dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for VSTM dated on 2018-05-17: 41 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-05-16: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VSTM dated on 2018-05-16: Verastem Oncology Prices 7.77M Shares At \$4.50/Share, Gross Proceeds From The Offering Are Expected To Be \$35M

Financial news for VSTM dated on 2018-05-16: Verastem Shares Down 13.6% After Co. Late Tuesday Announced \$35M Common Stock Offering

Financial news for VSTM dated on 2018-05-16: 26 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2018-05-16: Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

Financial news for VSTM dated on 2018-05-16: A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Housing Starts, Industrial Production Data

Financial news for VSTM dated on 2018-05-16: 8 Stocks To Watch For May 16, 2018

Financial news for VSTM dated on 2018-05-15: 7 Stocks Moving In Tuesday's After-Hours Session

Financial news for VSTM dated on 2018-05-14: 50 Biggest Movers From Friday

Financial news for VSTM dated on 2018-05-03: Verastem Q1 EPS \$(0.41) Misses \$(0.39) Estimate

Financial news for VSTM dated on 2018-05-02: Seaport Global Initiates Coverage On Verastem with Buy Rating, Announces \$14 Price Target

Financial news for VSTM dated on 2018-04-10: 40 Biggest Movers From Yesterday

Financial news for VSTM dated on 2018-04-09: Verastem Shares Up 10.8% After FDA Earlier Accepted New Drug Application For Duvelisib And Granted Priority Review

Financial news for VSTM dated on 2018-04-09: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for VSTM dated on 2018-04-09: Benzinga Pro's 5 Stocks To Watch Today

Financial news for VSTM dated on 2018-04-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for VSTM dated on 2018-04-09: Verastem Announces FDA Accepts New Drug Application for Duvelisib and Grants Priority Review

Financial news for VSTM dated on 2018-03-13: Verastem Reports FY EPS \$(1.76) vs \$(1.74) Est., No Sales

Financial news for VSTM dated on 2018-03-08: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for VSTM dated on 2018-02-07: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VSTM dated on 2018-02-07: Benzinga Pro's 5 Stocks To Watch Today

Financial news for VSTM dated on 2018-02-07: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VSTM dated on 2018-02-07: Verastem Submits New Drug Application to U.S. FDA for Duvelisib

Financial news for VSTM dated on 2018-01-30: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSTM dated on 2018-01-26: UPDATE: Verastem Says 'data support further exploration of duvelisib in combination with immunotherapeutic agents for the treatment of aggressive lymphomas'

Financial news for VSTM dated on 2018-01-26: Verastem Shares Spike Slightly Higher As Co. Issues Release Highlighting Preclinical Data At ASCO-SITC For Duvelisib In Combo With Immune Checkpoint

Financial news for VSTM dated on 2017-12-18: Verastem Files For 8,422,877 Shares Common Stock Offering, BTIG to Purchase The Shares At \$2.97/Share

Financial news for VSTM dated on 2017-12-18: 33 Biggest Movers From Friday

Financial news for VSTM dated on 2017-12-15: Mid-Afternoon Market Update: Dow Surges Over 150 Points; Longfin Shares Spike Higher

Financial news for VSTM dated on 2017-12-15: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2017-12-15: Mid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares Plummet

Financial news for VSTM dated on 2017-12-15: Mid-Morning Market Update: Markets Open Higher; Adobe Earnings Top Expectations

Financial news for VSTM dated on 2017-12-15: Verastem Prices \$25M Common Stock Offering

Financial news for VSTM dated on 2017-12-15: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2017-12-14: Verastem Announces \$25M Common Stock Offering

Financial news for VSTM dated on 2017-12-12: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VSTM dated on 2017-12-12: 42 Biggest Movers From Yesterday

Financial news for VSTM dated on 2017-12-11: Verastem Announces Phase 1 Duvelisib Data From ASH, Demonstrates Acceptable Safety Profile

Financial news for VSTM dated on 2017-12-11: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for VSTM dated on 2017-12-11: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for VSTM dated on 2017-12-11: 36 Biggest Movers From Friday

Financial news for VSTM dated on 2017-12-10: Verastem Announces Clinical Data from the Pivotal Phase 3 DUO Study Showing Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory CLL Leukemia and SLL at #ASH2017

Financial news for VSTM dated on 2017-12-08: 25 Stocks Moving In Friday's Mid-Day Session

Financial news for VSTM dated on 2017-12-08: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2017-12-01: 38 Biggest Movers From Yesterday

Financial news for VSTM dated on 2017-11-30: Verastem Shares Up 12.84% On ~4x Avg. Volume; Hearing Roth Capital Earlier Initiated The Stock With Buy Rating And Price Target Of \$12

Financial news for VSTM dated on 2017-11-30: 30 Stocks Moving In Thursday's Mid-Day Session

Financial news for VSTM dated on 2017-11-14: Stifel 2017 Healthcare Conference Begins Today, Presenters Include: Seres Therapeutics, Verastem, TherapeuticsMD, Aerie Pharmaceuticals, Mednax, Celgene, TransEnterix, Exelixis, Tandem Diabetes Care and Masimo

Financial news for VSTM dated on 2017-11-07: Verastem Reports Q3 EPS \$(0.61) vs \$(0.32) Est.

Financial news for VSTM dated on 2017-10-31: UPDATE: Verastem Reports Will Submit NDA For Duvelisib During Q1'18

Financial news for VSTM dated on 2017-10-31: Verastem Reports Regulatory Strategy For Duvelisib NDA: 'Plans to Submit a Single NDA Requesting Full Approval of Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'

Financial news for VSTM dated on 2017-10-18: 13 Stocks Moving In Wednesday's After-Hours Session

Financial news for VSTM dated on 2017-10-17: Verastem Announces a \$6M Milestone Payment to Infinity Pharma

Financial news for VSTM dated on 2017-10-11: Verastem Names NgocDiep Le CMO

Financial news for VSTM dated on 2017-09-25: Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma

Financial news for VSTM dated on 2017-09-11: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for VSTM dated on 2017-09-08: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2017-09-06: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Sarepta Shares Jump After Positive Results In DMD Treatment Study

Financial news for VSTM dated on 2017-09-06: Verastem Boosted After Positive Top-Line Data For Leukemia Treatment

Financial news for VSTM dated on 2017-09-06: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for VSTM dated on 2017-09-06: Mid-Day Market Update: Trivago Drops On Weak Outlook; Verastem Shares Surge

Financial news for VSTM dated on 2017-09-06: Mid-Morning Market Update: Markets Open Higher; G-III Apparel Tops Q2 Views

Financial news for VSTM dated on 2017-09-06: Cantor Fitzgerald Upgrades Verastem to Overweight

Financial news for VSTM dated on 2017-09-06: 25 Stocks Moving In Wednesday's Pre-

Market Session

Financial news for VSTM dated on 2017-09-06: Verastem's Phase 3 DUO Study Showed Statistically Significant Improvement

Financial news for VSTM dated on 2017-09-06: Verastem's Duvelisib Receives Fast Track Designation from the FDA

Financial news for VSTM dated on 2017-08-08: Verastem Reports Q2 Loss/Share \$(0.36) vs. \$(0.34) Est.

Financial news for VSTM dated on 2017-07-17: Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock

Financial news for VSTM dated on 2017-07-13: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for VSTM dated on 2017-07-11: Verastem Appoints Julie Feder CFO

Financial news for VSTM dated on 2017-07-11: Verastem Spikes to High of \$4.47 on Volume

Financial news for VSTM dated on 2017-07-07: 12 Biggest Mid-Day Gainers For Friday

Financial news for VSTM dated on 2017-07-07: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for VSTM dated on 2017-06-08: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for VSTM dated on 2017-06-07: Verastem Offers Long-Term Follow-Up Data From DYNAMO Study: Showed '47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma,' '88% of Patients had a Reduction in the Size of Target Lymph Nodes'

Financial news for VSTM dated on 2017-06-05: Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data

Financial news for VSTM dated on 2017-05-24: Verastem Shares Volatile Over Last Few Mins as Traders Circulating Word of Positive Mention from Microcap Newsletter on Agora

Financial news for VSTM dated on 2017-05-17: Verastem Director Timothy J Barberich Buys 30,000 Shares @ Avg Price: \$2.45 -Form4

Financial news for VSTM dated on 2017-05-10: Verastem Reports Q1 EPS \$(0.35) vs \$(0.35) Est.

Financial news for VSTM dated on 2017-04-13: Oppenheimer Initiates Coverage On Verastem with Outperform Rating, Announces \$6.00 Price Target

Financial news for VSTM dated on 2017-04-12: Hearing Oppenheimer Initiates On Verastem With Buy Rating and \$6 PT

Financial news for VSTM dated on 2017-04-02: Verastem Announces Data on Focal Adhesion Kinase Inhibitor Defactinib Presented at AACR 2017

Financial news for VSTM dated on 2017-03-31: 15 Biggest Mid-Day Losers For Friday

Financial news for VSTM dated on 2017-03-30: Verastem Files For \$150M Mixed Shelf Offering

Financial news for VSTM dated on 2017-03-24: H.C. Wainwright Reiterates Buy On Verastem, Raises Price Target To \$6.50

Financial news for VSTM dated on 2017-03-23: Verastem Reports FY16 EPS \$(0.99) vs \$(1.18) Est.

Financial news for VSTM dated on 2017-03-23: Verastem Reports FY16 EPS \$(0.99) vs. \$(1.61) YoY

Financial news for VSTM dated on 2017-03-23: Earnings Scheduled For March 23, 2017

Financial news for VSTM dated on 2017-03-13: 18 Biggest Mid-Day Gainers For Monday

Financial news for VSTM dated on 2017-03-13: Several Biotherapeutics Stocks Outperforming: Cerulean Pharma Up 44%, Adaptimmune 16%, Aurinia 15%, Versatem 14.5%, Heat Biologics 14%, Calithera 14%

Financial news for VSTM dated on 2017-01-26: Verastem Reports Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer

Financial news for VSTM dated on 2017-01-19: Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors

Financial news for VSTM dated on 2016-12-06: Verastem Presents Phase 2 DYNAMO Clinical Data at ASH 2016

Financial news for VSTM dated on 2016-11-07: Verastem Reports Q3 Loss/Share \$0.21 vs Est Loss/Share \$0.24

Financial news for VSTM dated on 2016-11-02: Verastem Licenses Duvelisib from Infinity Pharmaceuticals

Financial news for VSTM dated on 2016-08-08: Verastem Sees Having Sufficient Cash, Cash Equivalents, Short-Term Investments to Fund R&D Programs, Operations Into '18

Financial news for VSTM dated on 2016-08-08: Verastem Reports Q2 EPS \$(0.23) vs \$(0.29) Est.

Financial news for VSTM dated on 2016-05-09: Verastem Reports Q1 EPS \$(0.22) vs \$(0.30) Est.

Financial news for VSTM dated on 2016-04-18: Verastem Names Dr. Gregory Berk Chief Medical Officer

Financial news for VSTM dated on 2016-03-30: Verastem Reports Presentation of Data Supporting FAK Inhibition in Combo with Immunotherapy at Keystone Symposium on Cancer Pathophysiology

Financial news for VSTM dated on 2016-03-10: Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer

Financial news for VSTM dated on 2016-03-03: Mid-Morning Market Update: Markets Open Lower; Joy Global Reports Wider-Than-Expected Q1 Loss

Financial news for VSTM dated on 2016-03-03: UPDATE: Merck, Pfizer, and Verastem Combination Trial Of Avelumab and VS-6063 Expected To Begin In 2nd Half 2016

Financial news for VSTM dated on 2016-03-03: Verastem Reports FY15 EPS \$(1.61) vs. Prior Year Quarter \$(2.07)

Financial news for VSTM dated on 2016-03-03: Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Report Combination Trial of Avelumab and VS-6063 in Ovarian Cancer

Financial news for VSTM dated on 2016-01-06: Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer

Financial news for VSTM dated on 2015-11-09: Verastem Reports Q3 EPS (\$0.42) vs Est (\$0.44)

Financial news for VSTM dated on 2015-11-09: Verastem Reports Q3 EPS \$(0.42) vs \$(0.44) Est.

Financial news for VSTM dated on 2015-10-08: Verastem Reports Reduction Of Workforce By 50% To 20 Full Time Employees

Financial news for VSTM dated on 2015-09-30: Verastem Due Diligence: Cancels Phase II Study and Market Reacts - BrokerBank Securities

Financial news for VSTM dated on 2015-09-29: Benzinga's Top Downgrades

Financial news for VSTM dated on 2015-09-29: UBS Downgrades Verastem to Neutral, Lowers PT to \$16.00

Financial news for VSTM dated on 2015-09-29: Jefferies Downgrades Verastem to Hold

Financial news for VSTM dated on 2015-09-28: Mizuho Securities Downgrades Verastem to Neutral, Lowers PT to \$2.00

Financial news for VSTM dated on 2015-09-28: Morning Market Losers

Financial news for VSTM dated on 2015-09-28: Roth Capital Downgrades Verastem to Neutral

Financial news for VSTM dated on 2015-09-28: Benzinga's Top #PreMarket Losers

Financial news for VSTM dated on 2015-09-28: Shares of Verastem Trading Down to \$2.99, Down ~47% from Friday's Close

Financial news for VSTM dated on 2015-09-28: Shares of Verastem Resume Trade, Now Down to \$4.27

Financial news for VSTM dated on 2015-09-28: Shares of Verastem to Resume Trade at 7:30 a.m. EDT

Financial news for VSTM dated on 2015-09-28: Verastem Reports Stopping Enrollment in COMMAND Study of VS-6063

Financial news for VSTM dated on 2015-09-28: Verastem Shares Halted News Pending

Financial news for VSTM dated on 2015-09-24: Verastem Reports New Research Published in Journal Cell Related to Potential of FAK Inhibition for Enhancement of Efficacy of Anti-Tumor Immunotherapy

Financial news for VSTM dated on 2015-09-10: Roth's Pantginis Comments on Verastem: 'After Abstract Debacle, '6063 Data Impress in NSCLC,' Buy Rating, \$23 Price Target Reiterated

Financial news for VSTM dated on 2015-08-26: Stocks Hitting 52-Week Lows

Financial news for VSTM dated on 2015-08-26: Morning Market Losers

Financial news for VSTM dated on 2015-08-26: Benzinga's Top #PreMarket Losers

Financial news for VSTM dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for VSTM dated on 2015-08-10: Verastem Reports Q2 Loss \$0.42 vs Est Loss \$0.45

Financial news for VSTM dated on 2015-06-10: Verastem Announces Chief Medical Officer to Move to Advisory Role

Financial news for VSTM dated on 2015-04-27: Oppenheimer Assumes Verastem at Perform

Financial news for VSTM dated on 2015-04-22: Verastem Presents Encouraging Scientific Data on Preferential Targeting of Cancer Stem Cells at AACR

Financial news for VSTM dated on 2015-04-08: H.C. Wainwright Initiates Coverage on Verastem at Buy, Announces \$16.00 PT

Financial news for VSTM dated on 2015-04-02: Bind Therapeutics Inc, Noble Energy, Inc., Others Are Moving After-Hours

Financial news for VSTM dated on 2015-03-10: Verastem Reports FY14 Loss of \$2.07/Share vs Loss of \$2.08/Share Est.; Says Command Enrollment Remains On Track

Financial news for VSTM dated on 2015-02-13: Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

Financial news for VSTM dated on 2015-02-13: Verastem Receives FDA Orphan Designation for Defactinib for Ovarian Cancer

Financial news for VSTM dated on 2015-01-26: 3 Biotech IPOs Debuting This Week

Financial news for VSTM dated on 2015-01-22: Verastem Prices 7.25M Share Offering @\$6.50/Share

Financial news for VSTM dated on 2015-01-21: 5 Biotech Secondaries Traders Are Watching

Financial news for VSTM dated on 2015-01-20: Verastem Announces \$40M Proposed Public Offering of Common Stock

Financial news for VSTM dated on 2015-01-20: Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma

Financial news for VSTM dated on 2015-01-20: US Stock Futures Surge Ahead Of Earnings

Financial news for VSTM dated on 2015-01-20: Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma

Financial news for VSTM dated on 2015-01-13: What Investors Are Looking At In The Stem Cell Sector

Financial news for VSTM dated on 2014-12-24: Verastem Director Termeer Buys 19,100 Shares @\$8.09/Share -Form 4

Financial news for VSTM dated on 2014-12-22: Verastem COO Paterson Buys 2,000 Shares @\$8.52/Share -Form 4

Financial news for VSTM dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for VSTM dated on 2014-11-12: Verastem Director Lawton Buys 2,500 Shares @\$9.17/Share -Form 4

Financial news for VSTM dated on 2014-11-10: Verastem To Participate In Panel At The MassBio Patient Advocacy Summit

Financial news for VSTM dated on 2014-10-30: Verastem, Inc. Reports Q3 EPS of \$(0.52), Inline

Financial news for VSTM dated on 2014-08-07: Verastem Reports Q2 EPS -\$0.51 vs -\$0.51 Est. Does Not Compare

Financial news for VSTM dated on 2014-07-08: Oppenheimer Initiates Coverage on Verastem, Inc. at Market Perform, Announces \$8.99 PT

Financial news for VSTM dated on 2014-06-02: Verastem Presents Updated Clinical Data from VS-6063, Paclitaxel Combination Phase 1/1b Study in Patients with Ovarian Cancer at ASCO

Financial news for VSTM dated on 2014-05-08: Verastem, Inc. Reports Q1 EPS of \$(0.51) vs \$(0.43) Est

Financial news for VSTM dated on 2014-05-06: UPDATE: Deutsche Bank Initiates Coverage On Verastem On Multiple Positive Factors

Financial news for VSTM dated on 2014-05-06: Deutsche Bank Initiates Coverage on Verastem, Inc. at Buy, Announces \$14.00 PT

Financial news for VSTM dated on 2014-03-05: Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients; Completes Full Enrollment and was "Well Tolerated" at Each Dosage Level

Financial news for VSTM dated on 2014-02-25: Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718

Financial news for VSTM dated on 2014-02-04: Verastem Issued Japanese Patent for Dual mTORC1/2 and PI3K Inhibitor VS-5584

Financial news for VSTM dated on 2013-12-10: Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor

Financial news for VSTM dated on 2013-09-26: Verastem Begins Phase 2 Trial of Defatinib in Lunc Cancer

Financial news for VSTM dated on 2013-09-24: Verastem Initiates Defactinib Trial in Japan

Financial news for VSTM dated on 2013-08-15: Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter

Financial news for VSTM dated on 2013-08-13: Verastem, Inc. Reports Q2 EPS of \$(0.49) vs \$(0.41) Est

Financial news for VSTM dated on 2013-08-13: Earnings Scheduled For August 13, 2013

Financial news for VSTM dated on 2013-07-29: UPDATE: Jefferies Initiates Verastem at Buy on Cancer Research Potential

Financial news for VSTM dated on 2013-07-29: Benzinga's Top Initiations

Financial news for VSTM dated on 2013-07-29: Jefferies Initiates Coverage on Verastem, Inc. at Buy, Announces \$21.00 PT

Financial news for VSTM dated on 2013-07-29: Jefferies Initiates Coverage on Verastem, Inc. at Buy, Announces \$21.00 PT

Financial news for VSTM dated on 2013-07-24: Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma

Financial news for VSTM dated on 2013-07-23: Verastem Drug Achieves a Complete

Response in Platinum-Resistant Ovarian Cancer

Financial news for VSTM dated on 2013-07-23: Verastem Says CRL Confirmed in VS-6063 Trial

Financial news for VSTM dated on 2013-07-17: Market Wrap for Wednesday, July 17: Stocks Rise as Bernanke Emphasizes Flexibility of Stimulus Program

Financial news for VSTM dated on 2013-07-17: Verastem Announces Pricing of Public Offering of Common Stock At \$15

Financial news for VSTM dated on 2013-07-16: Verastem Announces Proposed Public Offering of Common Stock

Financial news for VSTM dated on 2013-07-12: UPDATE: Oppenheimer Raised PT on Verastem Following Analyst Day

Financial news for VSTM dated on 2013-07-11: Verastem Presents Results and Updated Development Plans

Financial news for VSTM dated on 2013-07-09: Benzinga's Volume Movers

Financial news for VSTM dated on 2013-07-09: Benzinga's Top Initiations

Financial news for VSTM dated on 2013-07-09: UPDATE: Cantor Fitzgerald Initiates Verastem at Buy on Compelling Mix of Catalysts

Financial news for VSTM dated on 2013-07-08: Cantor Fitzgerald Initiates Coverage on Verastem, Inc. at Buy, Announces \$22.00 PT

Financial news for VSTM dated on 2013-06-27: Verastem Successfully Completes Phase 1 Stage of Combination Trial of Cancer Stem Cell Inhibitor VS-6063 and Paclitaxel

Financial news for VSTM dated on 2013-06-26: Verastem Initiates Phase 1 Clinical Trial of VS-4718 in Patients with Advanced Cancer

Financial news for VSTM dated on 2013-06-13: Market Wrap for Thursday, June 13: Strong Economic Reports Trigger Stock Rally

Financial news for VSTM dated on 2013-06-13: Afternoon Market Gainers

Financial news for VSTM dated on 2013-06-13: Verastem Wins Orphan Medicinal Product Designation from EC for VS-6063

Financial news for VSTM dated on 2013-06-06: Verastem Appoints Robert Forrester as Chief Executive Officer

Financial news for VSTM dated on 2013-05-14: Jack Green Named Verastem CFO

Financial news for VSTM dated on 2013-03-27: Earnings Scheduled For March 27, 2013

Financial news for VSTM dated on 2013-03-13: Roth Capital Initiates Coverage on Verastem, Inc. at Buy, Announces \$18.00 PT

Financial news for VSTM dated on 2013-02-22: Guggenheim Securities Initiates Coverage on Verastem, Inc. at Buy, Announces \$16.00 PT

Financial news for VSTM dated on 2013-02-14: Verastem Files for Orphan Disease Status in US and EU for VS-6063 in Mesothelioma

Financial news for VSTM dated on 2013-02-08: From Earlier: JMP Securities Initiates Coverage on Verastem, Inc. at Market Outperform, Announces \$20.00 PT

Financial news for VSTM dated on 2013-02-06: Verastem Announces Publication of Data for VS-5584 in Molecular Cancer Therapeutics

Financial news for VSTM dated on 2013-01-09: Verastem Enters Agreement with LabCorp to Validate Biomarkers

Financial news for VSTM dated on 2012-11-13: Verastem Reports Q3 EPS \$-0.51 vs \$-0.36 Est

Financial news for VSTM dated on 2012-08-13: Verastem Reports Q2 EPS \$-0.34 vs \$-0.34 Est

Financial news for VSTM dated on 2012-07-12: A Peek Into The Market Before The Trading Starts

Financial news for VSTM dated on 2012-07-12: Verastem Enters Research Collaboration

with Eisai for Small Molecule Wnt Inhibitors

Financial news for VSTM dated on 2012-07-11: Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer

Financial news for VSTM dated on 2012-04-03: Verastem Announces Addition to Russell 2000 Index

Financial news for VSTM dated on 2012-03-15: Oppenheimer: Verastem Reports FY11 Results

Financial news for VSTM dated on 2012-03-07: UPDATE: Oppenheimer Initiates Verastem's Rating and PT

Financial news for VSTM dated on 2012-02-14: Longwood Reports 13.63% Stake in Verastem

Financial news for VSTM dated on 2012-02-02: From Earlier: Underwriters Exercise Over-Allotment Option for Verastem Initial Public Offering

Financial news for VSTM dated on 2012-02-01: Verastem IPO Launch Captures Investors Attention

Financial news for VSTM dated on 2012-01-27: Verastem raises \$55 mn in IPO

Financial news for VSTM dated on 2012-01-27: Verastem IPO Opens for Trading at \$11.10, after Pricing at \$10.00/Share